Apimeds Pharmaceuticals US, Inc. (APUS)
NYSEAMERICAN: APUS · Real-Time Price · USD
1.750
-0.060 (-3.31%)
At close: May 13, 2025, 4:00 PM
1.690
-0.060 (-3.43%)
Pre-market: May 14, 2025, 6:43 AM EDT
Company Description
Apimeds Pharmaceuticals US, Inc. operates as a clinical stage biopharmaceutical company in the United States.
It researches, develops, manufactures, commercializes, and sells Apitox, an active pharmaceutical ingredient for the treatment of inflammation and pain management symptoms associated with osteoarthritis and multiple sclerosis.
The company was incorporated in 2020 and is based in Hopewell, New Jersey.
Apimeds Pharmaceuticals US, Inc.
| Country | United States |
| Founded | 2020 |
| IPO Date | May 9, 2025 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 2 |
| CEO | Erik Emerson |
Contact Details
Address: 2 East Broad Street, 2nd Floor Hopewell, New Jersey 08525 United States | |
| Phone | 808 209 7887 |
| Website | apimedsus.com |
Stock Details
| Ticker Symbol | APUS |
| Exchange | NYSEAMERICAN |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $4.00 |
| CIK Code | 0001894525 |
| Employer ID | 85-1099700 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Christopher Kim, MD | Chairman and Chief Medical Officer |
| Erik Emerson | Chief Executive Officer and Chief Financial Officer |
| Jakap Koo | Director |
| Dr. Bennett Weintraub, PhD. | Director |
| Hankil Yoon | Director |
| Carol O’Donnell | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 12, 2025 | 8-K | Current Report |
| May 9, 2025 | 424B4 | Prospectus |
| May 5, 2025 | EFFECT | Notice of Effectiveness |
| May 2, 2025 | POS AM | Post-Effective amendments for registration statement |
| May 2, 2025 | 10-K/A | [Amend] Annual report |
| May 1, 2025 | POS AM | Post-Effective amendments for registration statement |
| Apr 17, 2025 | POS AM | Post-Effective amendments for registration statement |
| Apr 15, 2025 | 10-K | Annual Report |
| Apr 15, 2025 | 8-K | Current Report |
| Mar 31, 2025 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |